GentaGel-LR

GentaGel-LR

生物技术研究

Injectable, biodegradable local sustained release of antibiotics for prevention & treatment of infections.

关注

关于我们

GentaGel-LR was founded in late 2021 by Dr. Ariel Orbach, Mr. Eli Lerner, and Professor Abraham J. Domb. The company is based on a ground-breaking drug delivery technology invented by Prof. Domb, for the in-situ sustained release of antibiotics for the treatment and prevention of surgical site infections. GentaGel offers a local slow-release antibiotic treatment which is injected and continuously releases antibiotics (e.g., Gentamicin) for up to 60 days. The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area. Thus, GentaGel provides an effective antibiotic treatment while avoiding systemic side-effects and expensive cost-of-care. The Company is entering the clinical stage with a FIH Study to be conducted at the Sheba Medical Center, Israel.

网站
https://gentagel-lr.com/
所属行业
生物技术研究
规模
2-10 人
类型
私人持股
创立
2021
领域
Injectable, biodegradable local sustained release of antibiotics for prevention & treatment of infections

GentaGel-LR员工

查看全部员工

相似主页